PATENT CLAIM ANALYSIS

Application Number: 15774898
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["436", "071000"]

Abstract:
An objective biomarker is capable of evaluating the severity of depression and is clinically useful. The biomarker is used for evaluating the severity of depression, and includes at least one compound selected from the group made of 4-aminobutyric acid (γ (gamma)-aminobutyric acid: GABA), arginine, argininosuccinate, isoleucine, indole carboxaldehyde, potassium indoleacetate, carnitine, acetylcarnitine, ornithine, xanthurenate, kynurenate, kynurenine, citrate, creatine, creatinine, glutamine, dimethylglycine, serotonin, taurine, trimethyloxamine (TMAO), tryptophan, norvaline, 3-hydroxybutyrate, phenylalanine, proline, betaine, and lysine.

Claim (Index 37):
The method according to  claim 36 ,\n wherein the biomarker further contains at least one compound selected from the group consisting of N-acetylglutamate, alanine, xanthurenate, xanthosine, phenylalanine, and phosphoenolpyruvate.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 93.0
- Lexical Diversity: 1.69231
- Patent Class: 436.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14762426', '13318797', '14945200', '14903706', '14850933']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6604528044972482
- 35 USC 102 Novelty (BERT): 0.4875413299350692
- Combined Prediction Score: 0.6431616570410303
- Mean Citation Score: 204.961758
- Max Citation Score: 207.92635
- Similarity Product: 140.74992553862631

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test